Fixed-price program charges / margin erosion (the 2025 pattern) against one dominant customer
One-line thesis. A cheap, low-beta, dividend-paying defense prime with a fortress backlog and an irreplaceable franchise (F-35, missile defense, Space) — but 2025 was a margin-shock year (net income fell to $5.0B on program charges), growth is low-single-digit, and at only +3% to our base-case fair value the risk/reward is balanced rather than compelling. Watch, not Buy, until margin recovery is proven or the price is better.
◆ Synthos call — HoldLMT is a solid business largely reflected at ~$560 — fine to keep, no reason to chase; it gets interesting again below ~$476.
Downside Risk (lower = safer)
4/10 · Moderate
Beta 0.11 and a cheap ~18× forward multiple cushion downside, but 2.2× net-debt/EBITDA, single-customer (US gov) concentration and program-margin charges are real.
Growth Quality
5/10 · Moderate
~5% revenue CAGR and a margin-recovery EPS rebound off a weak 2025; solid ROIC ~17% and a durable moat, but low-growth and margin-fragile.
Exponential Potential
2/10 · Low
Low-single-digit, non-accelerating top line at a $126B cap in a budget-capped TAM — a compounder/income name, not an exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 7%/yrTo justify today’s $546, earnings would have to compound roughly 7% a year for 10 years (9% discount rate). Analysts forecast ~5%/yr, so the market is pricing in about what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Lockheed Martin builds the big-ticket hardware for the U.S. military and its allies: the F-35 fighter jet, missiles and missile-defense systems (Patriot, THAAD), military helicopters, and satellites. Almost all its money comes from the U.S. government and allied governments buying through the U.S. — so it is steady, but it lives and dies by the defense budget.
The stock is cheap — you pay about $18 for each dollar the company is expected to earn next year, which is inexpensive for a company this dominant, and it pays a solid dividend (~2.5%). The catch is that it barely grows (a few percent a year), and in 2025 profits took a real hit because some fixed-price programs cost more than planned.
Our verdict is Watch: it is a fine, sturdy, income-and-ballast holding, but at today's price it is roughly fairly valued, so there is no rush.
Here's what our three scores mean in everyday terms:
Downside Risk 4/10 (fairly safe). It barely moves when the overall market moves, it's cheap, and demand is government-backed — but it carries some debt and its profits can wobble when a program goes over budget.
Growth Quality 5/10 (average). A good, durable business earning healthy returns, but growing slowly and with margins that have proven fragile.
Exponential Potential 2/10 (low). Do not expect this to double quickly — it's a giant company in a budget-limited market. You own it for steady dividends and stability, not fireworks.
The one big worry: more of the fixed-price program charges that hammered 2025 profits, in a business almost entirely dependent on one customer (the U.S. government).
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = LMT · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$545.70
Market cap$126B
P/E trailing24×
P/E FY26E / FY27E18× / 17×
EV / Sales1.9×
EV / EBITDA17.1×
Gross margin9.8%
Net margin6.4%
Dividend yield2.50%
Beta0.106
52-wk range$411 – $677
RSI(14)49
50 / 200-DMA$520 / $541
12-mo return+17% (SPY +21%)
Street target$633 ($517–$700)
Analyst grades20 Buy · 16 Hold · 1 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on LMT · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Lockheed Martin (NYSE: LMT) is the world's largest defense contractor, founded 1912, headquartered in Bethesda, MD, with ~121,000 employees. It researches, designs, builds, and sustains advanced aerospace, defense, and space systems, selling primarily to the U.S. government and to allied governments via U.S.-government-facilitated foreign military sales. Fiscal year ends late December.
Segment revenue (FY2025, from filings):
Aeronautics — $30.3B (40%): combat and mobility aircraft, above all the F-35 (plus F-22, F-16, C-130).
Rotary and Mission Systems (RMS) — $17.3B (23%): Sikorsky helicopters, naval/radar/combat systems, C2, cyber, training.
Missiles and Fire Control (MFC) — $14.5B (19%): air/missile defense (Patriot/PAC-3, THAAD), precision strike (PrSM, HIMARS-related), fire control.
Space — $13.0B (17%): satellites, strategic/missile systems, Orion, classified.
Geographic mix (FY2025): United States $53.7B (72%) · Europe $8.8B · Asia-Pacific $7.8B · Middle East $2.9B · other $1.9B. Overwhelmingly domestic; the ~28% international slice (allied FMS) is the growth swing factor as European and Indo-Pacific defense budgets rise.
The strategic frame: an enormous, contracted backlog and near-monopoly positions (F-35 is the West's only fifth-gen mass fighter program) give revenue visibility, but the customer concentration and fixed-price-contract risk are structural.
2. The expert thesis (no KB coverage)
There is no expert coverage for LMT in the Synthos knowledge base — total_claims = 0, zero net-bullish voices. No claim IDs exist to cite, so this deep dive makes no appeal to expert conviction; the verdict is entirely fundamentals- and quant-driven and should be weighed as such. Where a name like this would normally carry a distilled panel of investor voices, here we have none, which is itself a reason the conviction rating is Low and the verdict is Watch rather than a higher-confidence call.
For external context only (not Synthos conviction): the sell-side is mildly constructive — 20 Buy, 16 Hold, 1 Sell, "Buy" consensus, with an FMP letter rating of B+. Treat that as background, not as our anchor.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
4 · Below-average risk
Beta 0.106 (nearly market-independent) and a cheap ~18× forward multiple cushion the downside; offset by net-debt/EBITDA 2.2×, single-customer (US gov) concentration, and the 2025 fixed-price program charges.
Growth Quality
5 · Average
~5% forward revenue CAGR, an EPS rebound off a depressed 2025, ROIC ~17%, and a genuine moat — but low growth and demonstrably fragile margins keep it middling.
Exponential Potential
2 · Low
Low-single-digit, non-accelerating revenue at a $126B cap in a budget-capped TAM. This is an income/defensive compounder, not an exponential.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Margins normalize fully, allied FMS accelerates, munitions "framework" volume ramps 3–4×. FY27E EPS beats to ~$34 (vs $32 cons); multiple re-rates to ~20× as growth/margin fears fade.
~$690 (+26%)
Base(our anchor)
Guidance roughly holds — FY26E EPS ~$29.9, FY27E ~$32; a low-growth defensive prime earns a ~17.5× multiple on FY27E.
~$560 (+3%)
Bear
Further fixed-price charges, a budget/CR (continuing-resolution) air-pocket, or F-35 delivery/margin trouble. FY27E EPS misses to ~$28; multiple de-rates to ~15×.
~$430 (−21%)
Synthos fair value = the base case, ~$560 (+3%), with the full $430–$690 span as the honest range. This anchor sits below the Street's $633 consensus — we are more cautious on the pace of margin recovery and apply a low-growth-appropriate multiple, whereas the Street's high of $700 implies a fuller re-rating. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). LMT is squarely a low-growth compounder / income name — the opposite of an exponential:
Forward growth: revenue CAGR FY25→FY30E ~4.6% ($75.1B → $93.9B est); EPS CAGR is higher (~13%, $21.56 → $38.98 est) but that is largely a margin-recovery rebound off a charge-depressed 2025 base, not durable acceleration.
Acceleration (the 2nd derivative) is flat-to-negative: revenue grew +5.6% (FY25) and consensus has +5.5% (FY26E) → +5.4% (FY27E) → ~+2% by FY30E. There is no inflection; growth is steady-to-decelerating.
Room to run: the addressable market (U.S. + allied defense procurement) is large but budget-capped and politically gated — it does not scale like a consumer or software TAM. At a $126B cap, a 5× would imply a ~$630B defense prime, which the budget math does not support on any near horizon.
Reinvestment runway: the "framework agreements" to lift munitions output 3–4× and heavy capex ($2.5–2.8B FY26E guided) are real reinvestment, but into a slow-compounding base.
Exponential Potential: Low (2/10). Own LMT for a ~2.5% dividend, buybacks, and low-beta ballast — not for a fast multibagger. A small, accelerating name with these returns-on-capital would score far higher; a $126B budget-capped prime does not.
The 2025 margin shock: net income fell to $5.02B (EPS $21.56) from FY24's $5.34B and FY23's $6.92B — driven by fixed-price program charges (notably a weak Q2'25: net income just $342M / EPS $1.46). Gross margin compressed to ~10% and net margin to 6.4% TTM. This is the single most important fact about the stock right now.
Quarterly trajectory: Q1'25 EPS $7.30 → Q2 $1.46 (charge quarter) → Q3 $6.98 → Q4 $5.82 → Q1'26 $6.44. The wild Q2'25 swing is exactly the fixed-price risk in action.
Margins: gross ~9.8% TTM, EBITDA ~11.3% TTM, net 6.4% TTM. Thin by design (cost-plus/large-program economics) and vulnerable to charges.
Returns on capital: ROIC ~16.8%, ROCE ~20% — genuinely good. ROE (74%) is optically huge but distorted by a small ($6.7B) equity base and buybacks; don't over-read it.
Cash flow: FY25 operating CF $8.56B, capex −$1.65B, FCF $6.91B (FCF/share ~$24.6). Note Q1'26 FCF was −$291M on working-capital timing — normal seasonality, but worth confirming reverses.
Balance sheet: total debt $21.7B, net debt $17.6B, net-debt/EBITDA 2.2×, current ratio 1.14×. Investment-grade and serviceable (interest coverage ~6.6×), but leverage is real and equity is thin.
LMT is cheap on forward earnings and the whole debate is whether 2025's margin damage is transient or structural. On live consensus: ~18× FY26E EPS ($29.9), ~17× FY27E ($32.0), ~14× FY30E ($39.0) — modest for a franchise this durable. Trailing looks richer (26× EPS) only because 2025 earnings were charge-depressed. On cash it screens fine: EV/EBITDA 17× TTM, EV/S 1.9×, P/FCF ~22×, FCF yield ~4.5%. A reverse read: today's ~$546 asks for little — roughly the guided low-single-digit growth plus a partial margin recovery. If margins normalize the multiple has room; if charges recur, "cheap" is a value trap. Street targets (context): consensus $633, high $700, low $517 — our $560 base is below consensus because we discount the margin-recovery pace and apply a low-growth multiple. Not expensive; a fairly-valued defensive, which is why the verdict is Watch rather than Buy.
7. Technicals (from the tech block)
Trend:mixed / repairing. $545.91 sits just above the 50-DMA ($520) but right around the 200-DMA ($540.5) — a stock trying to reclaim its long-term trend, not a clean uptrend. MACD −3.1 (mildly negative).
Location:−19.3% off the 52-week high ($676.70), +32.9% off the 52-week low ($410.74). The −19% is also the max drawdown from peak — a meaningful correction already absorbed.
Momentum: RSI(14) 49 — dead neutral; neither oversold nor overbought, no timing edge either way.
Relative strength (the tell): LMT +17.2% 12-mo vs SPY +20.6% and QQQ +30.3% — a laggard over the year, and −11.6% over 3 months vs SPY +13.7%. It has underperformed both the market and the Nasdaq.
Read: technicals are neutral-to-repairing and confirm the fundamental "no rush" stance. A hold above the 200-DMA (~$540) with margin proof would be constructive; a break back below the 50-DMA would argue for patience. No technical reason to chase.
8. Moat & competitive position
LMT's moat is structural: (1) sole-source, mission-critical franchises — the F-35 is the only Western fifth-gen fighter in mass production, and its missile-defense (PAC-3, THAAD) and Space portfolios have few substitutes; (2) decades-long program lock-in and sustainment tails — once a platform is fielded, LMT earns sustainment revenue for 30+ years; (3) regulatory/scale barriers — the qualified supplier base for these systems is tiny. The offsetting weakness is a near-monoxpsony customer (the U.S. government sets price, volume, and contract type) and fixed-price-contract exposure that turned 2025 into a charge year.
Peer set (market cap): direct defense primes — Northrop Grumman $78B, General Dynamics $101B, L3Harris $56B; broader industrials/aerospace in the FMP peer list — Boeing $179B, Honeywell $73B, Deere $168B, Parker-Hannifin $121B, TransDigm $75B, Trane $106B, ADP $97B. Among the pure primes, LMT is the largest and among the cheapest on forward earnings, reflecting its low growth and 2025 margin scare.
9. Management, capital allocation & guidance
Leadership: Chairman/President/CEO Jim Taiclet. Capital allocation is shareholder-friendly and disciplined: ~$6.1B returned in FY25 (dividends + buybacks) roughly matching FCF, net-debt/EBITDA held ~2.2×, capex stepping up ($2.5–2.8B FY26E guided) into munitions capacity.
Insider activity: the sampled window shows routine director phantom-stock awards and a small gift — no cluster of alarming discretionary open-market selling (most recent filings 2026-07-02). Neutral signal.
Management's own guidance (half-weighted — their own self-interested words): from the Q1'26 earnings release (SEC 8-K, filed 2026-04-23), management reaffirmed full-year 2026 guidance: sales $77.5–80.0B, business-segment operating profit $8,425–8,675M, diluted EPS $29.35–30.25, cash from operations $9,150–9,450M, capex $2,500–2,800M, and free cash flow $6.5–6.8B — framed as ~5% sales growth and ~25% operating-profit growth YoY. Management also touted "framework agreements" to raise munitions production rates "3–4× current rates." This is management's self-interested framing; we half-weight it, but the FY26 EPS/FCF guide anchors our base case.
10. Catalysts & what to watch
Next earnings: 2026-07-23 (Q2'26; Street EPS $7.22, revenue ~$19.4B). The key line: segment operating margins and whether any fresh program charges appear (Q2'25 was the disaster quarter — the YoY comp is easy, so watch the absolute margin).
FCF confirmation: Q1'26 FCF was −$291M on working-capital timing; watch it swing positive toward the $6.5–6.8B full-year guide.
F-35: delivery cadence, TR-3/Block 4 progress, and any renegotiated lot economics.
Munitions ramp: evidence the "framework agreements" convert to booked, higher-margin volume (Patriot/PAC-3, THAAD, PrSM).
Budget/political: U.S. defense appropriations, continuing-resolution risk, and allied (Europe/Indo-Pacific) FMS demand.
Thesis tripwires (what would change the call): a second year of fixed-price charges; segment margins failing to recover toward ~11%+; FCF missing the guided range; or a budget/CR air-pocket. Any of these pushes toward Avoid; clean margin recovery + a better entry pushes toward Buy.
11. Key risks
Fixed-price program charges (structural): 2025 proved these can gut a year's earnings (Q2'25 EPS $1.46). The dominant near-term risk.
Single-customer concentration: ~72% U.S. government revenue → exposed to budget cycles, CRs, procurement priorities, and pricing power that sits with the buyer.
Leverage / thin equity: net-debt/EBITDA 2.2× and a $6.7B equity base leave less cushion than the "defense blue chip" label implies.
Low growth / value-trap risk: if margins don't recover, a ~17× multiple on stagnant earnings can compress — "cheap" is not a floor.
No expert corroboration: with zero KB coverage, this call lacks the independent-voice cross-check we apply to conviction names — weight accordingly.
12. Verdict, position sizing & monitoring
Watch. LMT is a cheap, low-beta, dividend-paying prime with an irreplaceable franchise and a fortress backlog — genuinely ownable as ballast. But 2025 was a real margin shock, growth is low-single-digit, there is no expert conviction in the Synthos KB, and at only +3% to our ~$560 base-case fair value the risk/reward is balanced. That combination is a Watch, not a Buy: we want either proof that margins have normalized (a clean Q2'26) or a better entry (toward the low-$500s / our bear zone) before upgrading.
Sizing: if held today, treat as income/defensive ballast, ~1–3% — not a growth position. New money can wait for the 2026-07-23 print.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. Logged as a tracked Synthos call as of 2026-07-03 at $545.70.
Single biggest risk: recurrence of fixed-price program charges against a single dominant customer.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — LMT has no expert coverage in the Synthos KB, so no claim_ids are cited and no expert conviction is claimed. This note is explicitly fundamentals- and quant-driven.
Data as-of: fundamentals 2026-03-29 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release filed 2026-04-23. Forward figures are analyst consensus (FMP) or company guidance, labeled as estimates.
Management caveat: the FY2026 outlook in §9 is management's own, self-interested guidance, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").